The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Jiangsu Hengrui Medicine; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Jiangsu Hengrui Medicine; Taiho Pharmaceutical
Pembrolizumab for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.
 
Manish A. Shah
Consulting or Advisory Role - Lilly
Research Funding - Genentech (Inst); Sanofi (Inst)
 
Jaafar Bennouna
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche
 
Lin Shen
No Relationships to Disclose
 
Peter C. Enzinger
Consulting or Advisory Role - Amgen; Five Prime Therapeutics; Merck; Pfizer; Sirtex Medical
 
Qiao Li
Employment - Merck Sharp & Dohme
 
Ildiko Csiki
Employment - Merck Sharp & Dohme
 
Minori Koshiji
Employment - Merck Sharp & Dohme
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)